M62I mutation of DUSP6 was identified in all three osimertinib-resistant PDX tumors, while T846A, N850S, or I931T mutation of RASA1 was detected in at least one osimertinib-resistant PDX tumor. This evidence concerns the gene DUSP6 and neoplasm.